首页> 美国卫生研究院文献>BioMed Research International >Tuning Aerosol Particle Size Distribution of Metered Dose Inhalers Using Cosolvents and Surfactants
【2h】

Tuning Aerosol Particle Size Distribution of Metered Dose Inhalers Using Cosolvents and Surfactants

机译:使用助溶剂和表面活性剂调节定量吸入器的气溶胶粒径分布

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Objectives. The purpose of these studies was to understand the influence of cosolvent and surfactant contributions to particle size distributions emitted from solution metered dose inhalers (pMDIs) based on the propellant HFA 227. Methods. Two sets of formulations were prepared: (a) pMDIs-HFA 227 containing cosolvent (5–15% w/w ethanol) with constant surfactant (pluronic) concentration and (b) pMDIs-HFA 227 containing surfactant (0–5.45% w/w pluronic) with constant cosolvent concentration. Particle size distributions emitted from these pMDIs were analyzed using aerodynamic characterization (inertial impaction) and laser diffraction methods. Results. Both cosolvent and surfactant concentrations were positively correlated with median particle sizes; that is, drug particle size increased with increasing ethanol and pluronic concentrations. However, evaluation of particle size distributions showed that cosolvent caused reduction in the fine particle mode magnitude while the surfactant caused a shift in the mode position. These findings highlight the different mechanisms by which these components influence droplet formation and demonstrate the ability to utilize the different effects in formulations of pMDI-HFA 227 for independently modulating particle sizes in the respirable region. Conclusion. Potentially, the formulation design window generated using these excipients in combination could be used to match the particle size output of reformulated products to preexisting pMDI products.
机译:目标。这些研究的目的是了解助溶剂和表面活性剂对基于HFA 227推进剂的溶液计量吸入器(pMDIs)排放的粒度分布的影响。制备了两套制剂:(a)含助溶剂(5-15%w / w乙醇)的pMDIs-HFA 227,表面活性剂(多元醇)的浓度恒定;(b)含表面活性剂(0-5.45%w / w的pMDIs-HFA 227)助溶剂浓度恒定)。使用空气动力学表征(惯性碰撞)和激光衍射方法分析了这些pMDI发出的粒度分布。结果。助溶剂和表面活性剂的浓度均与中值粒径呈正相关。即,随着乙醇和普朗尼克浓度的增加,药物的粒径增加。然而,对粒度分布的评估表明,助溶剂引起细颗粒模式强度的降低,而表面活性剂引起模式位置的偏移。这些发现突显了这些成分影响液滴形成的不同机制,并证明了利用pMDI-HFA 227配方中的不同作用来独立调节可呼吸区域的粒径的能力。结论。潜在地,使用这些赋形剂组合生成的制剂设计窗口可用于将重新配制产品的粒径输出与现有pMDI产品进行匹配。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号